Compare FINW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | ALXO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.1M | 240.8M |
| IPO Year | 2021 | 2020 |
| Metric | FINW | ALXO |
|---|---|---|
| Price | $16.79 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 8.4K | ★ 771.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.51 | ★ 26.36 |
| EPS | ★ 1.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.49 | $0.41 |
| 52 Week High | $22.49 | $2.66 |
| Indicator | FINW | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 34.25 |
| Support Level | $16.39 | $1.41 |
| Resistance Level | $18.95 | $2.30 |
| Average True Range (ATR) | 0.54 | 0.16 |
| MACD | 0.21 | -0.04 |
| Stochastic Oscillator | 73.97 | 15.08 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.